← Back to Search
Synergistic Antitumor Activity Of Recombinant Human Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) In Combination With Carboplatin And Pemetrexed In Malignant Pleural Mesothelioma
G. Pasello, L. Urso, M. Silic-Benussi, M. Schiavon, I. Cavallari, G. Marulli, N. Nannini, F. Rea, V. Ciminale, A. Favaretto
Published 2014 · Medicine
Download PDFAnalyze on Scholarcy
Introduction: Malignant pleural mesothelioma (MPM) is an aggressive, currently incurable tumor with increasing incidence in industrialized countries. Tumor necrosis factor-related, apoptosis-inducing ligand (TRAIL) is a member of the TNF family, which induces cancer cell death through extrinsic apoptotic pathway, while sparing normal cells. The aim of this study was to investigate the antitumor activity of recombinant human Apo2L/TRAIL (dulanermin) in combination with chemotherapy in MPM in vitro and in vivo. Methods: In the present studies, we employed a panel of MPM cell lines to test the antitumor activity of recombinant human Apo2L/TRAIL (T) in combination with carboplatin and pemetrexed (CP) in vitro and SCID mice. Results: Results demonstrated a significant increase of apoptosis in cell lines treated with CPT compared with those receiving CP or T as single agents. This synergistic effect was dependent on the ability of CP to increase the expression of the TRAIL receptors DR4 and DR5 in a p53 manner. The CPT combination was also effective in blocking the growth of MPM cell lines in a SCID mice preclinical model. Conclusions: CPT increases MPM cell death in vitro and in vivo compared with CP. In vitro results suggest that chemotherapy sensitizes MPM to TRAIL-dependent apoptosis through p53 activation and subsequent upregulation of DRs.
This paper references
Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.
M. Nagane (2000)
Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.
J. Soria (2011)
A novel receptor for Apo2L/TRAIL contains a truncated death domain
S. Marsters (1997)
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
A. Ashkenazi (2002)
The clinical trail of TRAIL.
E. Duiker (2006)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Next generation sequencing in malignant pleural mesothelioma: preliminary data from a retrospective cohort of 123 patients
NS LoIaconoMarco (2013)
Transcriptional Repression of the Anti-apoptoticsurvivin Gene by Wild Type p53*
W. H. Hoffman (2002)
HGS - ETR 1 , a fully human TRAIL - receptor 1 monoclonal antibody , induces cell death in multiple tumour types in vitro and in vivo
L Pukac (2005)
Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL‐R1 and TRAIL‐R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin‐ and bortezomib‐induced cell death
G. Georgakis (2005)
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.
R. Herbst (2010)
Gemcitabine and vinorelbine in pemetrexed‐pretreated patients with malignant pleural mesothelioma
P. Zucali (2008)
Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.
G. Pasello (2011)
New insights into apoptosis signaling by Apo 2 L / TRAIL
F Gonzalvez (2010)
An antagonist decoy receptor and a death domain-containing receptor for TRAIL.
G. Pan (1997)
Additive effect of Apo2L/TRAIL and Adeno-p53 in the induction of apoptosis in myeloma cell lines.
Q. Liu (2001)
Apo2 Ligand/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cooperates with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve Survival
H. Jin (2004)
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
G. Ceresoli (2011)
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family*
R. Pitti (1996)
Absence of p53 mutations in malignant mesotheliomas.
O. Mor (1997)
Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL*
J. G. Emery (1998)
A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance.
Ki-Up Kim (2005)
Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer.
J. Soria (2010)
An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma.
G. Pasello (2013)
Gruppo di lavoro ReNaM. [Epidemiological surveillance of malignant mesothelioma cases in Italy: incidence and asbestos exposure figures by the Italian mesothelioma registry
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
B. Castagneto (2008)
New insights into apoptosis signaling by Apo2L/TRAIL
F. Gonzálvez (2010)
Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin
L. Belyanskaya (2007)
Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study
A. Xanthopoulos (2008)
Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.
J. Sheridan (1997)
Targeting p 53 as a therapeutic strategy in sensitizing TRAIL - induced apoptosis in cancer cells
J Zhao (2012)
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
How TRAIL Kills Cancer Cells, But Not Normal Cells
T. Gura (1997)
TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages
Bao-Zhu Yuan (2012)
Malignant mesothelioma: global incidence and relationship with asbestos.
C. Bianchi (2007)
HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo
L. Pukac (2005)
[Epidemiological surveillance of malignant mesothelioma cases in Italy: incidence and asbestos exposure figures by the Italian mesothelioma registry (ReNaM)].
A. Marinaccio (2007)
Increased Expression of Death Receptors 4 and 5 Synergizes the Apoptosis Response to Combined Treatment with Etoposide and TRAIL
S. Gibson (2000)
The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice
B. Hylander (2005)
Safety and antitumor activity of recombinant soluble Apo2 ligand.
A. Ashkenazi (1999)
Apo2L/TRAIL and its death and decoy receptors
H N LeBlanc (2003)
Phase II study of peme - trexed plus carboplatin in malignant pleural mesothelioma
GL Ceresoli (2006)
Phase III study of peme - trexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
NJ Vogelzang (2003)
Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety.
S. Kelley (2001)
α-Tocopheryl succinate and TRAIL selectively synergise in induction of apoptosis in human malignant mesothelioma cells
M. Tomasetti (2004)
Update on the molecular biology of malignant mesothelioma
A. Lee (2007)
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
A. Santoro (2008)
The Receptor for the Cytotoxic Ligand TRAIL
G. Pan (1997)
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells.
Jing Zhao (2012)
Malignant mesothelioma cells are rapidly sensitized to TRAIL-induced apoptosis by low-dose anisomycin via Bim
Keith S. Abayasiriwardana (2007)
FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells
Maria Rita Rippo (2004)
Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).
A. Ashkenazi (2008)
Additive effect of Apo 2 L / TRAIL and Adeno - p 53 in the induction of apoptosis in myeloma cell lines
Q Liu (2001)
Scagliotti Giorgio V. Next generation sequencing in malignant pleural mesothelioma: preliminary data from a retrospective cohort of 123 patients
N S Lo Iacono Marco (2013)
Intracellular-signaling tumor-regression modeling of the pro-apoptotic receptor agonists dulanermin and conatumumab
B. Kay (2012)
Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy.
A. Chinnaiyan (2000)
A Histone Deacetylase Inhibitor LBH589 Downregulates XIAP in Mesothelioma Cell Lines Which is Likely Responsible for Increased Apoptosis With TRAIL
J. Symanowski (2009)
Phase I dose - escalation study of recombinant human Apo 2 L / TRAIL , a dual proapoptotic receptor agonist , in patients with advanced cancer
RS Herbst (2010)
Retreatment with peme - trexed - based chemotherapy in patients with malignant pleural mesothelioma
GL Ceresoli (2011)
Mechanisms of resistance to TRAIL-induced apoptosis in cancer
L. Zhang (2005)
This paper is referenced by
PKC-δ/PKC-α activity balance regulates the lethal effects of cisplatin.
A. Muscella (2015)
Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists
L. Urso (2017)
MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data
G. Pasello (2015)
Lung delivery of MSCs expressing anti-cancer protein TRAIL visualised with 89Zr-oxine PET-CT
P. S. Patrick (2020)
Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment.
L. Urso (2016)
Schedule-dependent cytotoxicity of sunitinib and TRAIL in human non-small cell lung cancer cells with or without EGFR and KRAS mutations
Yong-Xia Bao (2016)
Developing TRAIL/TRAIL death receptor-based cancer therapies
Xun Yuan (2018)